Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

Item

http://www.wikidata.org/entity/Q28181168

Q28181168

about

Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials Aspirin and clopidogrel resistance: an emerging clinical entity Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'Aspirin and clopidogrel resistance: consideration and management Prasugrel Optimizing platelet P2Y12 inhibition for patients undergoing PCI Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study Clopidogrel: an updated and comprehensive review Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents.Clinical importance of aspirin and clopidogrel resistance Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Optimal oral antithrombotic regimes for patients with acute coronary syndrome: a network meta-analysis Clopidogrel use in coronary artery disease.Platelet P2 receptors: old and new targets for antithrombotic drugs.Pharmacological antithrombotic adjuncts to percutaneous coronary intervention.Clopidogrel resistance--the cardiologist's perspective.Antiplatelet drugs in cardiological practice: established strategies and new developments Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.Prasugrel for the treatment of patients with acute coronary syndrome.Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.Platelet interactions as therapeutic targets for prevention of atherothrombosis.Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.Platelet P2Y12 receptor inhibition by thienopyridines: status and future.Clinical pharmacology of antithrombotic drugs in coronary artery disease.Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence.Platelet reactivity and nonresponse to dual antiplatelet therapy: a review.Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Prasugrel: a critical comparison with clopidogrel.Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.A comparison of the metabolism of clopidogrel and prasugrel.

P2860

Q24203035-A988C230-8055-49C3-AF59-7C5CB622CBAC Q26782970-4C643729-9698-40E0-BF92-74CEBBA01BDF Q28194021-F491B6E0-5707-4A1B-8A6B-3344F672BAE5 Q28196661-DE176D48-683C-4230-BC5F-B011C30DAE29 Q28200552-2F9115BC-D1CB-44F0-BFC5-CB905EA709CD Q28200610-C750FEB8-7347-4529-9BB8-B4E97943A20E Q28210429-0750A341-4C48-414E-951E-DFFA10464912 Q28218094-9D2FC792-5796-4CDC-B539-39348C4C0AF8 Q28218790-BEBAA858-9B1A-47DE-A7E6-10FDFAAD3F9C Q28219411-D3D5BC0B-CF65-432A-9683-FB42378EDB28 Q28220433-7F5D5FBC-848F-42F5-8FEA-ADB8C097CFC7 Q33393888-0883E372-440B-4791-8595-8D762A8ACD3C Q33685876-EFC4218A-0D39-43B3-B586-807298027BFA Q34382431-E40A19D1-39F1-4507-BF48-0EFFC9E2D865 Q34390050-03E695DC-9D18-4215-99FF-191143F12CE6 Q34771381-F22D95C5-F0FF-4DFA-A994-0FBCF653A7E0 Q35116512-F2523EC1-3777-41FA-9143-FAA225CE87AB Q36351993-68E53DF3-D28E-42F3-B894-ABDE3584CD9A Q36691632-DEE48A4D-7FCB-4D54-A9E5-C733DE5F6F90 Q36787291-5BA97EFB-A75E-434A-8BA8-6DC7DFA4F9F2 Q36819608-32CE30E1-047B-4EF3-B2E8-C45C96B6E0CB Q36835862-748554BC-CE64-4C1D-B6CF-5A889EEFE195 Q36941850-4B7D8AEB-5A99-4AB3-BD3A-2D53A3CBB176 Q37339517-EB19EF75-531A-465D-9FC9-AF5FC1A9BCD6 Q37380507-64F57CEF-B35A-4135-A299-8C6F5F4FBCB2 Q37451509-F8804687-712B-4306-9B65-DE6A56FA036C Q37479088-C0D459A4-F1B3-442A-8F09-6166E2081068 Q37486601-3C7FBF53-86A6-4436-A706-0F4BEF58D81A Q37486621-DFC3E9C6-E6AF-41B8-9709-CF9A602D75A4 Q37532491-BA9FB970-331C-4F9E-861B-D49FF696F1B3 Q37579228-8AE5AAB7-8BF6-4B93-AAB9-59E4B0A2A002 Q37591007-FF527ECE-7371-4BB6-B91D-AE8E94DDA248 Q37608580-E3C265DA-EC88-479C-A0D4-98066B9209FD Q37618798-EDAF35EE-ACFD-4424-806E-3E3E7668A2BA Q37629641-8BEFEABE-EEB3-49EA-B2AA-CE654C5DE105 Q37641320-EC5A6A12-FB31-401B-9735-218C6FCCD294 Q37641606-CCC8D440-D636-4071-8541-3091DD2F08B9 Q37704842-EA0CF47B-DE61-4A94-B6EB-9B977B9D4EA3 Q37714189-2577DA18-C097-434F-9185-4D3A9E13278B Q37788682-BFADC419-09A6-4E77-BF42-6BC8769B7FCD

P2860

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

Item

http://www.wikidata.org/entity/Q28181168

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu